A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This trial is evaluating the anti-tumor activity and side effects of panobinostat in treating
patients with osteosarcoma, malignant rhabdoid tumor/atypical teratoid rhabdoid tumor
(MRT/ATRT), and neuroblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
Australian & New Zealand Children's Haematology/Oncology Group
Collaborators:
National Health and Medical Research Council, Australia Secura Bio Secura Bio, Inc.